GRAIL Anticipates Early Q1 2027 FDA Decision for Galleri Test and Updates Revenue Growth Outlook
During its Q3 2026 earnings call, GRAIL, Inc. (GRAL) provided key updates regarding the regulatory timeline for its Galleri multi-cancer early detection test. CEO Joshua Ofman indicated that following a favorable vote from the FDA's Advisory Committee and recent journal publications of NHS-Galleri and PATHFINDER-2 results, the company expects a final FDA decision by early Q1 2027. In addition to regulatory progress, GRAIL updated its financial guidance, projecting revenue growth for the Galleri product to be between 17% and 21% in 2026. These updates reflect the company's momentum as it moves toward potential commercial scaling following clinical validation milestones.
Tickers: $GRAL
Topics: Clinical Trial Results FDA Approval Status Q3 Earnings Insights